

Copyright Notice

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components aren't assigned by the AMA, aren't part of CPT, and the AMA isn't recommending their use. The AMA doesn't directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Coverage & Billing Information for the 2024 Quarterly Code Update

Background

Iowa Medicaid has reviewed the **Q4 2024** Billing Code Update to determine coverage and billing guidelines. The Iowa Medicaid coverage and billing information provided in this bulletin is effective **10/1/2024**. This bulletin serves as a notice of the following information:

Table 1

- New Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **10/1/2024**.

Table 2

- New Current Dental Terminology (CDT®) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 3

- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Coverage and billing for these codes applies to dates of service on or after **10/1/2024**.

Table 4

- International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) codes. Coverage and billing for these codes applies to dates of service on or after **10/1/2024**.

Table 5

- Modifiers included in the code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 6

- CPT®, CDT®, & HCPCS codes that would be considered Outpatient Hospital on or after **10/1/2024**.

Table 7

- Non-Covered Codes - CPT®, CDT®, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective **10/1/2024**.

Table 8

- Deleted Codes - CPT®, CDT®, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been discontinued effective **9/30/2024**



Managed Care Organization (MCOs) establish and publish reimbursement, PA, and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCP with which the member is enrolled.

Iowa Medicaid Provider Services:

- Phone: 1-800-338-7909
- Email: imeproviderservices@hhs.iowa.gov

Wellpoint Iowa, Inc.:

- Phone: 1-833-731-2143
- Email: ProviderSolutionsIA@wellpoint.com
- Website: <https://www.provider.wellpoint.com/iowa-provider/home>

Iowa Total Care:

- Phone: 1-833-404-1061
- Email: providerrelations@iowatotalcare.com
- Website: <https://www.iowatotalcare.com>

Molina Healthcare of Iowa:

- Phone: 1-844-236-1464
- Email: aproviderrelations@molinahealthcare.com
- Website: <https://www.molinahealthcare.com/providers/ia/medicaid/home.aspx>
- Provider portal: <https://www.availity.com/molinahealthcare>

The **Q4 2024** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at www.cms.gov.

The **Q4** code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at cms.gov. If there is a replacement code, Iowa Medicaid has added the replacement code for which there were deleted codes effective as of **10/1/2024**.

Iowa Medicaid will update the fee schedule as rates become available.

Table 1 – CPT® & HCPCS Codes
[Back to top](#)

Code	Description (Table 1)	Effective Date
90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for IM use	10/1/2024
90684	Pneumococcal conjugate vaccine, 21 valent (pcv21), for intramuscular	10/1/2024
A9610	Xenon xe-129 hyperpolarized gas, diagnostic, per study	10/1/2024
C9169	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1	10/1/2024
C9170	Injection, tarlatamab-dlle, 1	10/1/2024
C9172	Injection, fidanacogene elaparvovec-dzkt, per therapeutic	10/1/2024
J0175	Injection, donanemab-azbt, 2	10/1/2024
J1171	Injection, hydromorphone, 0.1	10/1/2024
J2002	Injection, lidocaine hcl in 5% dextrose, 1	10/1/2024
J2003	Injection, lidocaine hydrochloride, 1	10/1/2024
J2004	Injection, lidocaine hcl with epinephrine, 1	10/1/2024
J2252	Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to J2250, 1	10/1/2024
J2601	Injection, vasopressin (baxter), 1	10/1/2024
J8522	Capecitabine, oral, 50	10/1/2024
J8541	Dexamethasone (hemady), oral, 0.25	10/1/2024
J9329	Injection, tislelizumab-jsgr, 1	10/1/2024

Code	Description (Table 1)	Effective Date
L1006	Scoliosis orthosis, sagittal-coronal control provided by a rigid lateral frame, extends from axilla to trochanter, includes all accessory pads, straps and interface, prefabricated item that has been trimmed, bent, molded,	10/1/2024
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1	10/1/2024
Q5136	Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1	10/1/2024

Table 2 – CDT©
[Back to top](#)

Code	Description	Effective Date
N/A	N/A	N/A

Table 3 – ICD-10-CM Codes
[Back to top](#)

Code	Description (Table 3)	Effective Date
A41.54	Sepsis due to Acinetobacter baumannii	10/1/2024
B96.83	Acinetobacter baumannii as the cause of diseases classified elsewhere	10/1/2024
D13.91	Familial adenomatous polyposis	10/1/2024
D13.99	Benign neoplasm of ill-defined sites within the digestive system	10/1/2024
D48.110	Desmoid tumor of head and neck	10/1/2024
D48.111	Desmoid tumor of chest wall	10/1/2024
D48.112	Desmoid tumor, intrathoracic	10/1/2024
D48.113	Desmoid tumor of abdominal wall	10/1/2024
D48.114	Desmoid tumor, intraabdominal	10/1/2024
D48.115	Desmoid tumor of upper extremity and shoulder girdle	10/1/2024

D48.116	Desmoid tumor of lower extremity and pelvic girdle	10/1/2024
D48.117	Desmoid tumor of back	10/1/2024
D48.118	Desmoid tumor of other site	10/1/2024
D48.119	Desmoid tumor of unspecified site	10/1/2024
D48.19	Other specified neoplasm of uncertain behavior of connective and other soft tissue	10/1/2024
D57.04	Hb-SS disease with dactylitis	10/1/2024
D57.214	Sickle-cell/Hb-C disease with dactylitis	10/1/2024
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	10/1/2024
D57.434	Sickle-cell thalassemia beta zero with dactylitis	10/1/2024
D57.454	Sickle-cell thalassemia beta plus with dactylitis	10/1/2024
D57.814	Other sickle-cell disorders with dactylitis	10/1/2024
D61.02	Shwachman-Diamond syndrome	10/1/2024
D89.84	IgG4-related disease	10/1/2024
E20.810	Autosomal dominant hypocalcemia	10/1/2024
E20.811	Secondary hypoparathyroidism in diseases classified elsewhere	10/1/2024
E20.812	Autoimmune hypoparathyroidism	10/1/2024
E20.818	Other specified hypoparathyroidism due to impaired parathyroid hormone secretion	10/1/2024
E20.819	Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified	10/1/2024
E20.89	Other specified hypoparathyroidism	10/1/2024
E74.05	Lysosome-associated membrane protein 2 [LAMP2] deficiency	10/1/2024

E75.27	Pelizaeus-Merzbacher disease	10/1/2024
E75.28	Canavan disease	10/1/2024
E79.81	Aicardi-Goutières syndrome	10/1/2024
E79.82	Hereditary xanthinuria	10/1/2024
E79.89	Other specified disorders of purine and pyrimidine metabolism	10/1/2024
E88.43	Disorders of mitochondrial tRNA synthetases	10/1/2024
E88.810	Metabolic syndrome	10/1/2024
E88.811	Insulin resistance syndrome, Type A	10/1/2024
E88.818	Other insulin resistance	10/1/2024
E88.819	Insulin resistance, unspecified	10/1/2024
E88.A	Wasting disease (syndrome) due to underlying condition	10/1/2024
G11.5	Hypomyelination - hypogonadotropic hypogonadism - hypodontia	10/1/2024
G11.6	Leukodystrophy with vanishing white matter disease	10/1/2024
G20.A1	Parkinson's disease without dyskinesia, without mention of fluctuations	10/1/2024
G20.A2	Parkinson's disease without dyskinesia, with fluctuations	10/1/2024
G20.B1	Parkinson's disease with dyskinesia, without mention of fluctuations	10/1/2024
G20.B2	Parkinson's disease with dyskinesia, with fluctuations	10/1/2024
G20.C	Parkinsonism, unspecified	10/1/2024
G23.3	Hypomyelination with atrophy of the basal ganglia and cerebellum	10/1/2024
G31.80	Leukodystrophy, unspecified	10/1/2024
G31.86	Alexander disease	10/1/2024
G37.81	Myelin oligodendrocyte glycoprotein antibody disease	10/1/2024

G37.89	Other specified demyelinating diseases of central nervous system	10/1/2024
G40.C01	Lafora progressive myoclonus epilepsy, not intractable, with status epilepticus	10/1/2024
G40.C09	Lafora progressive myoclonus epilepsy, not intractable, without status epilepticus	10/1/2024
G40.C11	Lafora progressive myoclonus epilepsy, intractable, with status epilepticus	10/1/2024
G40.C19	Lafora progressive myoclonus epilepsy, intractable, without status epilepticus	10/1/2024
G43.E01	Chronic migraine with aura, not intractable, with status migrainosus	10/1/2024
G43.E09	Chronic migraine with aura, not intractable, without status migrainosus	10/1/2024
G43.E11	Chronic migraine with aura, intractable, with status migrainosus	10/1/2024
G43.E19	Chronic migraine with aura, intractable, without status migrainosus	10/1/2024
G90.B	LMNB1-related autosomal dominant leukodystrophy	10/1/2024
G93.42	Megaloencephalic leukoencephalopathy with subcortical cysts	10/1/2024
G93.43	Leukoencephalopathy with calcifications and cysts	10/1/2024
G93.44	Adult-onset leukodystrophy with axonal spheroids	10/1/2024
H36.811	Nonproliferative sickle-cell retinopathy, right eye	10/1/2024
H36.812	Nonproliferative sickle-cell retinopathy, left eye	10/1/2024
H36.813	Nonproliferative sickle-cell retinopathy, bilateral	10/1/2024
H36.819	Nonproliferative sickle-cell retinopathy, unspecified eye	10/1/2024
H36.821	Proliferative sickle-cell retinopathy, right eye	10/1/2024
H36.822	Proliferative sickle-cell retinopathy, left eye	10/1/2024
H36.823	Proliferative sickle-cell retinopathy, bilateral	10/1/2024
H36.829	Proliferative sickle-cell retinopathy, unspecified eye	10/1/2024
H36.89	Other retinal disorders in diseases classified elsewhere	10/1/2024

H50.621	Inferior oblique muscle entrapment, right eye	10/1/2024
H50.622	Inferior oblique muscle entrapment, left eye	10/1/2024
H50.629	Inferior oblique muscle entrapment, unspecified eye	10/1/2024
H50.631	Inferior rectus muscle entrapment, right eye	10/1/2024
H50.632	Inferior rectus muscle entrapment, left eye	10/1/2024
H50.639	Inferior rectus muscle entrapment, unspecified eye	10/1/2024
H50.641	Lateral rectus muscle entrapment, right eye	10/1/2024
H50.642	Lateral rectus muscle entrapment, left eye	10/1/2024
H50.649	Lateral rectus muscle entrapment, unspecified eye	10/1/2024
H50.651	Medial rectus muscle entrapment, right eye	10/1/2024
H50.652	Medial rectus muscle entrapment, left eye	10/1/2024
H50.659	Medial rectus muscle entrapment, unspecified eye	10/1/2024
H50.661	Superior oblique muscle entrapment, right eye	10/1/2024
H50.662	Superior oblique muscle entrapment, left eye	10/1/2024
H50.669	Superior oblique muscle entrapment, unspecified eye	10/1/2024
H50.671	Superior rectus muscle entrapment, right eye	10/1/2024
H50.672	Superior rectus muscle entrapment, left eye	10/1/2024
H50.679	Superior rectus muscle entrapment, unspecified eye	10/1/2024
H50.681	Extraocular muscle entrapment, unspecified, right eye	10/1/2024
H50.682	Extraocular muscle entrapment, unspecified, left eye	10/1/2024
H50.689	Extraocular muscle entrapment, unspecified, unspecified eye	10/1/2024
H57.8A1	Foreign body sensation, right eye	10/1/2024

H57.8A2	Foreign body sensation, left eye	10/1/2024
H57.8A3	Foreign body sensation, bilateral eyes	10/1/2024
H57.8A9	Foreign body sensation, unspecified eye	10/1/2024
I1A.0	Resistant hypertension	10/1/2024
I20.81	Angina pectoris with coronary microvascular dysfunction	10/1/2024
I20.89	Other forms of angina pectoris	10/1/2024
I21.B	Myocardial infarction with coronary microvascular dysfunction	10/1/2024
I24.81	Acute coronary microvascular dysfunction	10/1/2024
I24.89	Other forms of acute ischemic heart disease	10/1/2024
I25.85	Chronic coronary microvascular dysfunction	10/1/2024
I47.10	Supraventricular tachycardia, unspecified	10/1/2024
I47.11	Inappropriate sinus tachycardia, so stated	10/1/2024
I47.19	Other supraventricular tachycardia	10/1/2024
J15.61	Pneumonia due to Acinetobacter baumannii	10/1/2024
J15.69	Pneumonia due to other Gram-negative bacteria	10/1/2024
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	10/1/2024
J44.89	Other specified chronic obstructive pulmonary disease	10/1/2024
J4A.0	Restrictive allograft syndrome	10/1/2024
J4A.8	Other chronic lung allograft dysfunction	10/1/2024
J4A.9	Chronic lung allograft dysfunction, unspecified	10/1/2024
K35.200	Acute appendicitis with generalized peritonitis, without perforation or abscess	10/1/2024
K35.201	Acute appendicitis with generalized peritonitis, with perforation, without abscess	10/1/2024

K35.209	Acute appendicitis with generalized peritonitis, without abscess, unspecified as to perforation	10/1/2024
K35.210	Acute appendicitis with generalized peritonitis, without perforation, with abscess	10/1/2024
K35.211	Acute appendicitis with generalized peritonitis, with perforation and abscess	10/1/2024
K35.219	Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation	10/1/2024
K63.8211	Small intestinal bacterial overgrowth, hydrogen-subtype	10/1/2024
K63.8212	Small intestinal bacterial overgrowth, hydrogen sulfide-subtype	10/1/2024
K63.8219	Small intestinal bacterial overgrowth, unspecified	10/1/2024
K63.822	Small intestinal fungal overgrowth	10/1/2024
K63.829	Intestinal methanogen overgrowth, unspecified	10/1/2024
K68.2	Retroperitoneal fibrosis	10/1/2024
K68.3	Retroperitoneal hematoma	10/1/2024
K90.821	Short bowel syndrome with colon in continuity	10/1/2024
K90.822	Short bowel syndrome without colon in continuity	10/1/2024
K90.829	Short bowel syndrome, unspecified	10/1/2024
K90.83	Intestinal failure	10/1/2024
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	10/1/2024
M80.0B1D	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing	10/1/2024
M80.0B1G	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing	10/1/2024

M80.0B1K	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion	10/1/2024
M80.0B1P	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion	10/1/2024
M80.0B1S	Age-related osteoporosis with current pathological fracture, right pelvis, sequela	10/1/2024
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	10/1/2024
M80.0B2D	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing	10/1/2024
M80.0B2G	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing	10/1/2024
M80.0B2K	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion	10/1/2024
M80.0B2P	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion	10/1/2024
M80.0B2S	Age-related osteoporosis with current pathological fracture, left pelvis, sequela	10/1/2024
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	10/1/2024
M80.0B9D	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing	10/1/2024
M80.0B9G	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing	10/1/2024
M80.0B9K	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion	10/1/2024

M80.0B9P	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion	10/1/2024
M80.0B9S	Age-related osteoporosis with current pathological fracture, unspecified pelvis, sequela	10/1/2024
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	10/1/2024
M80.8B1D	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing	10/1/2024
M80.8B1G	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing	10/1/2024
M80.8B1K	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion	10/1/2024
M80.8B1P	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion	10/1/2024
M80.8B1S	Other osteoporosis with current pathological fracture, right pelvis, sequela	10/1/2024
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	10/1/2024
M80.8B2D	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing	10/1/2024
M80.8B2G	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing	10/1/2024
M80.8B2K	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion	10/1/2024
M80.8B2P	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion	10/1/2024

M80.8B2S	Other osteoporosis with current pathological fracture, left pelvis, sequela	10/1/2024
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	10/1/2024
M80.8B9D	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing	10/1/2024
M80.8B9G	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing	10/1/2024
M80.8B9K	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion	10/1/2024
M80.8B9P	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion	10/1/2024
M80.8B9S	Other osteoporosis with current pathological fracture, unspecified pelvis, sequela	10/1/2024
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	10/1/2024
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	10/1/2024
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	10/1/2024
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	10/1/2024
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	10/1/2024
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	10/1/2024
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	10/1/2024

N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	10/1/2024
N04.21	Primary membranous nephropathy with nephrotic syndrome	10/1/2024
N04.22	Secondary membranous nephropathy with nephrotic syndrome	10/1/2024
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	10/1/2024
N06.20	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	10/1/2024
N06.21	Primary membranous nephropathy with isolated proteinuria	10/1/2024
N06.22	Secondary membranous nephropathy with isolated proteinuria	10/1/2024
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	10/1/2024
O26.641	Intrahepatic cholestasis of pregnancy, first trimester	10/1/2024
O26.642	Intrahepatic cholestasis of pregnancy, second trimester	10/1/2024
O26.643	Intrahepatic cholestasis of pregnancy, third trimester	10/1/2024
O26.649	Intrahepatic cholestasis of pregnancy, unspecified trimester	10/1/2024
O90.41	Hepatorenal syndrome following labor and delivery	10/1/2024
O90.49	Other postpartum acute kidney failure	10/1/2024
Q44.70	Other congenital malformation of liver, unspecified	10/1/2024
Q44.71	Alagille syndrome	10/1/2024
Q44.79	Other congenital malformations of liver	10/1/2024
Q75.001	Craniosynostosis unspecified, unilateral	10/1/2024
Q75.002	Craniosynostosis unspecified, bilateral	10/1/2024
Q75.009	Craniosynostosis unspecified	10/1/2024
Q75.01	Sagittal craniosynostosis	10/1/2024
Q75.021	Coronal craniosynostosis unilateral	10/1/2024

Q75.022	Coronal craniosynostosis bilateral	10/1/2024
Q75.029	Coronal craniosynostosis unspecified	10/1/2024
Q75.03	Metopic craniosynostosis	10/1/2024
Q75.041	Lambdoid craniosynostosis, unilateral	10/1/2024
Q75.042	Lambdoid craniosynostosis, bilateral	10/1/2024
Q75.049	Lambdoid craniosynostosis, unspecified	10/1/2024
Q75.051	Cloverleaf skull	10/1/2024
Q75.052	Pansynostosis	10/1/2024
Q75.058	Other multi-suture craniosynostosis	10/1/2024
Q75.08	Other single-suture craniosynostosis	10/1/2024
Q87.83	Bardet-Biedl syndrome	10/1/2024
Q87.84	Laurence-Moon syndrome	10/1/2024
Q87.85	MED13L syndrome	10/1/2024
Q93.52	Phelan-McDermid syndrome	10/1/2024
R09.A0	Foreign body sensation, unspecified	10/1/2024
R09.A1	Foreign body sensation, nose	10/1/2024
R09.A2	Foreign body sensation, throat	10/1/2024
R09.A9	Foreign body sensation, other site	10/1/2024
R40.2A	Nontraumatic coma due to underlying condition	10/1/2024
R92.30	Dense breasts, unspecified	10/1/2024
R92.311	Mammographic fatty tissue density, right breast	10/1/2024
R92.312	Mammographic fatty tissue density, left breast	10/1/2024

R92.313	Mammographic fatty tissue density, bilateral breasts	10/1/2024
R92.321	Mammographic fibroglandular density, right breast	10/1/2024
R92.322	Mammographic fibroglandular density, left breast	10/1/2024
R92.323	Mammographic fibroglandular density, bilateral breasts	10/1/2024
R92.331	Mammographic heterogeneous density, right breast	10/1/2024
R92.332	Mammographic heterogeneous density, left breast	10/1/2024
R92.333	Mammographic heterogeneous density, bilateral breasts	10/1/2024
R92.341	Mammographic extreme density, right breast	10/1/2024
R92.342	Mammographic extreme density, left breast	10/1/2024
R92.343	Mammographic extreme density, bilateral breasts	10/1/2024
T56.821A	Toxic effect of gadolinium, accidental (unintentional), initial encounter	10/1/2024
T56.821D	Toxic effect of gadolinium, accidental (unintentional), subsequent encounter	10/1/2024
T56.821S	Toxic effect of gadolinium, accidental (unintentional), sequela	10/1/2024
T56.822A	Toxic effect of gadolinium, intentional self-harm, initial encounter	10/1/2024
T56.822D	Toxic effect of gadolinium, intentional self-harm, subsequent encounter	10/1/2024
T56.822S	Toxic effect of gadolinium, intentional self-harm, sequela	10/1/2024
T56.823A	Toxic effect of gadolinium, assault, initial encounter	10/1/2024
T56.823D	Toxic effect of gadolinium, assault, subsequent encounter	10/1/2024
T56.823S	Toxic effect of gadolinium, assault, sequela	10/1/2024
T56.824A	Toxic effect of gadolinium, undetermined, initial encounter	10/1/2024
T56.824D	Toxic effect of gadolinium, undetermined, subsequent encounter	10/1/2024
T56.824S	Toxic effect of gadolinium, undetermined, sequela	10/1/2024

W44.8XXA	Other foreign body entering into or through a natural orifice, initial encounter	10/1/2024
W44.8XXD	Other foreign body entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.8XXS	Other foreign body entering into or through a natural orifice, sequela	10/1/2024
W44.9XXA	Unspecified foreign body entering into or through a natural orifice, initial encounter	10/1/2024
W44.9XXD	Unspecified foreign body entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.9XXS	Unspecified foreign body entering into or through a natural orifice, sequela	10/1/2024
W44.A0XA	Battery unspecified, entering into or through a natural orifice, initial encounter	10/1/2024
W44.A0XD	Battery unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.A0XS	Battery unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.A1XA	Button battery entering into or through a natural orifice, initial encounter	10/1/2024
W44.A1XD	Button battery entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.A1XS	Button battery entering into or through a natural orifice, sequela	10/1/2024
W44.A9XA	Other batteries entering into or through a natural orifice, initial encounter	10/1/2024
W44.A9XD	Other batteries entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.A9XS	Other batteries entering into or through a natural orifice, sequela	10/1/2024
W44.B0XA	Plastic object unspecified, entering into or through a natural orifice, initial encounter	10/1/2024
W44.B0XD	Plastic object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024

W44.B0XS	Plastic object unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.B1XA	Plastic bead entering into or through a natural orifice, initial encounter	10/1/2024
W44.B1XD	Plastic bead entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.B1XS	Plastic bead entering into or through a natural orifice, sequela	10/1/2024
W44.B2XA	Plastic coin entering into or through a natural orifice, initial encounter	10/1/2024
W44.B2XD	Plastic coin entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.B2XS	Plastic coin entering into or through a natural orifice, sequela	10/1/2024
W44.B3XA	Plastic toy and toy part entering into or through a natural orifice, initial encounter	10/1/2024
W44.B3XD	Plastic toy and toy part entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.B3XS	Plastic toy and toy part entering into or through a natural orifice, sequela	10/1/2024
W44.B4XA	Plastic jewelry entering into or through a natural orifice, initial encounter	10/1/2024
W44.B4XD	Plastic jewelry entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.B4XS	Plastic jewelry entering into or through a natural orifice, sequela	10/1/2024
W44.B5XA	Plastic bottle entering into or through a natural orifice, initial encounter	10/1/2024
W44.B5XD	Plastic bottle entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.B5XS	Plastic bottle entering into or through a natural orifice, sequela	10/1/2024
W44.B9XA	Other plastic object entering into or through a natural orifice, initial encounter	10/1/2024
W44.B9XD	Other plastic object entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.B9XS	Other plastic object entering into or through a natural orifice, sequela	10/1/2024
W44.C0XA	Glass unspecified, entering into or through a natural orifice, initial encounter	10/1/2024

W44.C0XD	Glass unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.C0XS	Glass unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.C1XA	Sharp glass entering into or through a natural orifice, initial encounter	10/1/2024
W44.C1XD	Sharp glass entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.C1XS	Sharp glass entering into or through a natural orifice, sequela	10/1/2024
W44.C2XA	Intact glass entering into or through a natural orifice, initial encounter	10/1/2024
W44.C2XD	Intact glass entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.C2XS	Intact glass entering into or through a natural orifice, sequela	10/1/2024
W44.D0XA	Magnetic metal object unspecified, entering into or through a natural orifice, initial encounter	10/1/2024
W44.D0XD	Magnetic metal object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.D0XS	Magnetic metal object unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.D1XA	Magnetic metal bead entering into or through a natural orifice, initial encounter	10/1/2024
W44.D1XD	Magnetic metal bead entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.D1XS	Magnetic metal bead entering into or through a natural orifice, sequela	10/1/2024
W44.D2XA	Magnetic metal coin entering into or through a natural orifice, initial encounter	10/1/2024
W44.D2XD	Magnetic metal coin entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.D2XS	Magnetic metal coin entering into or through a natural orifice, sequela	10/1/2024

W44.D3XA	Magnetic metal toy entering into or through a natural orifice, initial encounter	10/1/2024
W44.D3XD	Magnetic metal toy entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.D3XS	Magnetic metal toy entering into or through a natural orifice, sequela	10/1/2024
W44.D4XA	Magnetic metal jewelry entering into or through a natural orifice, initial encounter	10/1/2024
W44.D4XD	Magnetic metal jewelry entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.D4XS	Magnetic metal jewelry entering into or through a natural orifice, sequela	10/1/2024
W44.D9XA	Other magnetic metal objects entering into or through a natural orifice, initial encounter	10/1/2024
W44.D9XD	Other magnetic metal objects entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.D9XS	Other magnetic metal objects entering into or through a natural orifice, sequela	10/1/2024
W44.E0XA	Non-magnetic metal object unspecified, entering into or through a natural orifice, initial encounter	10/1/2024
W44.E0XD	Non-magnetic metal object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.E0XS	Non-magnetic metal object unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.E1XA	Non-magnetic metal bead entering into or through a natural orifice, initial encounter	10/1/2024
W44.E1XD	Non-magnetic metal bead entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.E1XS	Non-magnetic metal bead entering into or through a natural orifice, sequela	10/1/2024

W44.E2XA	Non-magnetic metal coin entering into or through a natural orifice, initial encounter	10/1/2024
W44.E2XD	Non-magnetic metal coin entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.E2XS	Non-magnetic metal coin entering into or through a natural orifice, sequela	10/1/2024
W44.E3XA	Non-magnetic metal toy entering into or through a natural orifice, initial encounter	10/1/2024
W44.E3XD	Non-magnetic metal toy entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.E3XS	Non-magnetic metal toy entering into or through a natural orifice, sequela	10/1/2024
W44.E4XA	Non-magnetic metal jewelry entering into or through a natural orifice, initial encounter	10/1/2024
W44.E4XD	Non-magnetic metal jewelry entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.E4XS	Non-magnetic metal jewelry entering into or through a natural orifice, sequela	10/1/2024
W44.E9XA	Other non-magnetic metal objects entering into or through a natural orifice, initial encounter	10/1/2024
W44.E9XD	Other non-magnetic metal objects entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.E9XS	Other non-magnetic metal objects entering into or through a natural orifice, sequela	10/1/2024
W44.F0XA	Objects of natural or organic material unspecified, entering into or through a natural orifice, initial encounter	10/1/2024
W44.F0XD	Objects of natural or organic material unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024

W44.F0XS	Objects of natural or organic material unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.F1XA	Bezoar entering into or through a natural orifice, initial encounter	10/1/2024
W44.F1XD	Bezoar entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.F1XS	Bezoar entering into or through a natural orifice, sequela	10/1/2024
W44.F2XA	Rubber band entering into or through a natural orifice, initial encounter	10/1/2024
W44.F2XD	Rubber band entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.F2XS	Rubber band entering into or through a natural orifice, sequela	10/1/2024
W44.F3XA	Food entering into or through a natural orifice, initial encounter	10/1/2024
W44.F3XD	Food entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.F3XS	Food entering into or through a natural orifice, sequela	10/1/2024
W44.F4XA	Insect entering into or through a natural orifice, initial encounter	10/1/2024
W44.F4XD	Insect entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.F4XS	Insect entering into or through a natural orifice, sequela	10/1/2024
W44.F9XA	Other object of natural or organic material, entering into or through a natural orifice, initial encounter	10/1/2024
W44.F9XD	Other object of natural or organic material, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.F9XS	Other object of natural or organic material, entering into or through a natural orifice, sequela	10/1/2024
W44.G0XA	Other non-organic objects unspecified, entering into or through a natural orifice, initial encounter	10/1/2024

W44.G0XD	Other non-organic objects unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.G0XS	Other non-organic objects unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.G1XA	Audio device entering into or through a natural orifice, initial encounter	10/1/2024
W44.G1XD	Audio device entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.G1XS	Audio device entering into or through a natural orifice, sequela	10/1/2024
W44.G2XA	Combination metal and plastic toy and toy part entering into or through natural orifice, initial encounter	10/1/2024
W44.G2XD	Combination metal and plastic toy and toy part entering into or through natural orifice, subsequent encounter	10/1/2024
W44.G2XS	Combination metal and plastic toy and toy part entering into or through natural orifice, sequela	10/1/2024
W44.G3XA	Combination metal and plastic jewelry entering into or through a natural orifice, initial encounter	10/1/2024
W44.G3XD	Combination metal and plastic jewelry entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.G3XS	Combination metal and plastic jewelry entering into or through a natural orifice, sequela	10/1/2024
W44.G9XA	Other non-organic objects entering into or through a natural orifice, initial encounter	10/1/2024
W44.G9XD	Other non-organic objects entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.G9XS	Other non-organic objects entering into or through a natural orifice, sequela	10/1/2024

W44.H0XA	Other sharp object unspecified, entering into or through a natural orifice, initial encounter	10/1/2024
W44.H0XD	Other sharp object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.H0XS	Other sharp object unspecified, entering into or through a natural orifice, sequela	10/1/2024
W44.H1XA	Needle entering into or through a natural orifice, initial encounter	10/1/2024
W44.H1XD	Needle entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.H1XS	Needle entering into or through a natural orifice, sequela	10/1/2024
W44.H2XA	Knife, sword or dagger entering into or through a natural orifice, initial encounter	10/1/2024
W44.H2XD	Knife, sword or dagger entering into or through a natural orifice, subsequent encounter	10/1/2024
W44.H2XS	Knife, sword or dagger entering into or through a natural orifice, sequela	10/1/2024
Z02.84	Encounter for child welfare exam	10/1/2024
Z05.81	Observation and evaluation of newborn for suspected condition related to home physiologic monitoring device ruled out	10/1/2024
Z05.89	Observation and evaluation of newborn for other specified suspected condition ruled out	10/1/2024
Z16.13	Resistance to carbapenem	10/1/2024
Z22.340	Carrier of carbapenem-resistant <i>Acinetobacter baumannii</i>	10/1/2024
Z22.341	Carrier of carbapenem-sensitive <i>Acinetobacter baumannii</i>	10/1/2024
Z22.349	Carrier of <i>Acinetobacter baumannii</i> , unspecified	10/1/2024
Z22.350	Carrier of carbapenem-resistant Enterobacterales	10/1/2024
Z22.358	Carrier of other Enterobacterales	10/1/2024

Z22.359	Carrier of Enterobacterales, unspecified	10/1/2024
Z29.81	Encounter for HIV pre-exposure prophylaxis	10/1/2024
Z29.89	Encounter for other specified prophylactic measures	10/1/2024
Z62.23	Child in custody of non-parental relative	10/1/2024
Z62.24	Child in custody of non-relative guardian	10/1/2024
Z62.823	Parent-step child conflict	10/1/2024
Z62.831	Non-parental relative-child conflict	10/1/2024
Z62.832	Non-relative guardian-child conflict	10/1/2024
Z62.833	Group home staff-child conflict	10/1/2024
Z62.892	Runaway [from current living environment]	10/1/2024
Z83.710	Family history of adenomatous and serrated polyps	10/1/2024
Z83.711	Family history of hyperplastic colon polyps	10/1/2024
Z83.718	Other family history of colon polyps	10/1/2024
Z83.719	Family history of colon polyps, unspecified	10/1/2024
Z91.85	Personal history of military service	10/1/2024
Z91.A41	Caregiver's other noncompliance with patient's medication regimen due to financial hardship	10/1/2024
Z91.A48	Caregiver's other noncompliance with patient's medication regimen for other reason	10/1/2024
Z91.A51	Caregiver's noncompliance with patient's renal dialysis due to financial hardship	10/1/2024
Z91.A58	Caregiver's noncompliance with patient's renal dialysis for other reason	10/1/2024

Z91.A91 Caregiver's noncompliance with patient's other medical treatment and regimen due to financial hardship 10/1/2024

Z91.A98 Caregiver's noncompliance with patient's other medical treatment and regimen for other reason 10/1/2024

Table 4 – ICD-10-PCS Codes

[Back to top](#)

Code	Description	Effective Date
02HW3RZ	Insertion of Short-term External Heart Assist System into Thoracic Aorta, Descending, Percutaneous Approach	10/1/2024
02PW3RZ	Removal of Short-term External Heart Assist System from Thoracic Aorta, Descending, Percutaneous Approach	10/1/2024
02WW3RZ	Revision of Short-term External Heart Assist System in Thoracic Aorta, Descending, Percutaneous Approach	10/1/2024
0CSS0ZZ	Reposition Larynx, Open Approach	10/1/2024
0CSS7ZZ	Reposition Larynx, Via Natural or Artificial Opening	10/1/2024
0CSS8ZZ	Reposition Larynx, Via Natural or Artificial Opening Endoscopic	10/1/2024
0DH17JZ	Insertion of Magnetic Lengthening Device into Upper Esophagus, Via Natural or Artificial Opening	10/1/2024
0DH27JZ	Insertion of Magnetic Lengthening Device into Middle Esophagus, Via Natural or Artificial Opening	10/1/2024
0DH37JZ	Insertion of Magnetic Lengthening Device into Lower Esophagus, Via Natural or Artificial Opening	10/1/2024
0WHC0GZ	Insertion of Defibrillator Lead into Mediastinum, Open Approach	10/1/2024
0WHC3GZ	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Approach	10/1/2024

0WHC4GZ	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Endoscopic Approach	10/1/2024
0WPC0GZ	Removal of Defibrillator Lead from Mediastinum, Open Approach	10/1/2024
0WPC3GZ	Removal of Defibrillator Lead from Mediastinum, Percutaneous Approach	10/1/2024
0WPC4GZ	Removal of Defibrillator Lead from Mediastinum, Percutaneous Endoscopic Approach	10/1/2024
0WPCXGZ	Removal of Defibrillator Lead from Mediastinum, External Approach	10/1/2024
0WWC0GZ	Revision of Defibrillator Lead in Mediastinum, Open Approach	10/1/2024
0WWC3GZ	Revision of Defibrillator Lead in Mediastinum, Percutaneous Approach	10/1/2024
0WWC4GZ	Revision of Defibrillator Lead in Mediastinum, Percutaneous Endoscopic Approach	10/1/2024
0WWCXGZ	Revision of Defibrillator Lead in Mediastinum, External Approach	10/1/2024
5A09B5K	Assistance with Respiratory Ventilation, Less than 8 Consecutive Hours, Intubated Prone Positioning	10/1/2024
5A09C5K	Assistance with Respiratory Ventilation, 8-24 Consecutive Hours, Intubated Prone Positioning	10/1/2024
5A09D5K	Assistance with Respiratory Ventilation, Greater than 24 Consecutive Hours, Intubated Prone Positioning	10/1/2024
8E0U0EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Open Approach	10/1/2024
8E0U3EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Approach	10/1/2024
8E0U4EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Endoscopic Approach	10/1/2024

8E0U7EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening	10/1/2024
8E0U8EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening Endoscopic	10/1/2024
8E0W0EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Open Approach	10/1/2024
8E0W3EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Approach	10/1/2024
8E0W4EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Endoscopic Approach	10/1/2024
8E0W7EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening	10/1/2024
8E0W8EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening Endoscopic	10/1/2024
X051329	Destruction of Renal Sympathetic Nerve(s) using Ultrasound Ablation, Percutaneous Approach, New Technology Group 9	10/1/2024
X2H03R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Inferior Vena Cava, Percutaneous Approach, New Technology Group 9	10/1/2024
X2H13R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Superior Vena Cava, Percutaneous Approach, New Technology Group 9	10/1/2024
X2H20R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Right Femoral Vein, Open Approach, New Technology Group 9	10/1/2024
X2H30R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Left Femoral Vein, Open Approach, New Technology Group 9	10/1/2024

X2H63V9	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Atrium, Percutaneous Approach, New Technology Group 9	10/1/2024
X2HK3V9	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Ventricle, Percutaneous Approach, New Technology Group 9	10/1/2024
X2HL0F9	Insertion of Conduit to Short-term External Heart Assist System into Right Axillary Artery, Open Approach, New Technology Group 9	10/1/2024
X2HM0F9	Insertion of Conduit to Short-term External Heart Assist System into Left Axillary Artery, Open Approach, New Technology Group 9	10/1/2024
X2HX0F9	Insertion of Conduit to Short-term External Heart Assist System into Thoracic Aorta, Ascending, Open Approach, New Technology Group 9	10/1/2024
X2KH3D9	Bypass Right Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	10/1/2024
X2KH3E9	Bypass Right Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	10/1/2024
X2KJ3D9	Bypass Left Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	10/1/2024
X2KJ3E9	Bypass Left Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	10/1/2024
X2U4079	Supplement Coronary Artery/Arteries with Vein Graft Extraluminal Support Device(s), Open Approach, New Technology Group 9	10/1/2024
X2UQ0P9	Supplement Right Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	10/1/2024
X2UR0P9	Supplement Left Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	10/1/2024

XNHG0F9	Insertion of Tibial Extension with Motion Sensors into Right Tibia, Open Approach, New Technology Group 9	10/1/2024
XNHH0F9	Insertion of Tibial Extension with Motion Sensors into Left Tibia, Open Approach, New Technology Group 9	10/1/2024
XNR80D9	Replacement of Skull with Ultrasound Penetrable Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2024
XNRL099	Replacement of Right Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2024
XNRM099	Replacement of Left Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2024
XRGJ0B9	Fusion of Right Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2024
XRGK0B9	Fusion of Left Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2024
XRGL0B9	Fusion of Right Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2024
XRGM0B9	Fusion of Left Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2024
XW013L9	Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	10/1/2024
XW013S9	Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	10/1/2024
XW033K9	Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2024

XW033P9	Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW033Q9	Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW033R9	Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW043K9	Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW043P9	Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW043Q9	Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW043R9	Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW053T9	Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9	10/1/2024
XW0DXJ9	Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9	10/1/2024
XW0DXN9	Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9	10/1/2024
XW133H9	Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2024
XW143H9	Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2024

XX20X89	Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9	10/1/2024
XX2F3W9	Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9	10/1/2024
XXE2X19	Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9	10/1/2024
XXE5XY9	Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9	10/1/2024

Table 5 – Modifiers
[Back to top](#)

Code	Description	Effective Date
N/A	N/A	N/A

Table 6 – Outpatient Hospital
[Back to top](#)

Code	Description (Table 6)	Effective Date
90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for IM use	10/1/2024
90684	Pneumococcal conjugate vaccine, 21 valent (pcv21), for intramuscular	10/1/2024
C9169	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1	10/1/2024
C9170	Injection, tarlatamab-dlle, 1	10/1/2024
C9172	Injection, fidanacogene elaparvovec-dzkt, per therapeutic	10/1/2024
J0175	Injection, donanemab-azbt, 2	10/1/2024
J1171	Injection, hydromorphone, 0.1	10/1/2024

Code	Description (Table 6)	Effective Date
J2002	Injection, lidocaine hcl in 5% dextrose, 1	10/1/2024
J2003	Injection, lidocaine hydrochloride, 1	10/1/2024
J2004	Injection, lidocaine hcl with epinephrine, 1	10/1/2024
J2252	Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to J2250, 1	10/1/2024
J2601	Injection, vasopressin (baxter), 1	10/1/2024
J8522	Capecitabine, oral, 50	10/1/2024
J8541	Dexamethasone (hemady), oral, 0.25	10/1/2024
J9329	Injection, tislelizumab-jsgr, 1	10/1/2024
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1	10/1/2024
Q5136	Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1	10/1/2024

Table 7 – Non-covered Codes
[Back to top](#)

Code	Description (Table 7)	Effective Date
0476U	Drug metabolism, psychiatry, whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported	10/1/2024
0477U	Drug metabolism, psychiatry, whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported	10/1/2024
0478U	Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9	10/1/2024

0479U	Tau, phosphorylated,pTau217	10/1/2024
0480U	Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen	10/1/2024
0481U	IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing	10/1/2024
0482U	Obstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 and placental growth factor, serum, ratio reported for sFlt1/PlGF, with risk of progression for preeclampsia with severe features within 2	10/1/2024
0483U	Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone	10/1/2024
0484U	Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide	10/1/2024
0485U	Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small	10/1/2024
0486U	Oncology (pan-solid tumor), nextgeneration sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor	10/1/2024
0487U	Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidycorrected gene copy number amplifications and losses, gene	10/1/2024

0488U	Obstetrics (fetal antigen noninvasive prenatal test), cellfree DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized	10/1/2024
0489U	Obstetrics (single-gene noninvasive prenatal test), cellfree DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage	10/1/2024
0490U	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma associated antigen, CD34 and CD45 protein	10/1/2024
0491U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers,	10/1/2024
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers,	10/1/2024
0493U	Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using nextgeneration sequencing, plasma, reported as percentage of donor derived cell-free	10/1/2024
0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative	10/1/2024
0495U	Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative	10/1/2024
0496U	Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or	10/1/2024

0497U	Oncology (prostate), mRNA geneexpression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalinfixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score	10/1/2024
0498U	Oncology (colorectal), nextgeneration sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern	10/1/2024
0499U	Oncology (colorectal and lung), DNA from formalin-fixed paraffinembedded (FFPE) tissue, nextgeneration sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation	10/1/2024
0500U	Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118-9_118-2del, S56F,	10/1/2024
0501U	Oncology (colorectal), blood, quantitative measurement of cellfree DNA	10/1/2024
0502U	Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk	10/1/2024
0503U	Neurology (Alzheimer disease), beta amyloid (A β 40, A β 42, A β 42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/nptau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass	10/1/2024
0504U	Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, realtime PCR, reported as positive or negative for each	10/1/2024
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each	10/1/2024
0506U	Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's	10/1/2024

0507U	Oncology (ovarian), DNA, wholegenome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not	10/1/2024
0508U	Transplantation medicine, quantification of donor-derived cell-free DNA using 40 singlenucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cellfree DNA with risk for	10/1/2024
0509U	Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for	10/1/2024
0510U	Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA wholetranscriptome data, reported as probability of predicted molecular	10/1/2024
0511U	Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each	10/1/2024
0512U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffinembedded (FFPE) tissue, reported as increased	10/1/2024
0513U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalinixed	10/1/2024
0514U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as	10/1/2024
0515U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as	10/1/2024

0516U	Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer	10/1/2024
0517U	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed	10/1/2024
0518U	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed	10/1/2024
0519U	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed,	10/1/2024
0520U	Therapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed	10/1/2024
A2027	Matriderm, per square	10/1/2024
A2028	Micromatrix flex, per	10/1/2024
A2029	Mirotract wound matrix sheet, per cubic	10/1/2024
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per	10/1/2024
A4544	Electrode for external lower extremity nerve stimulator for restless legs	10/1/2024
A4545	Supplies and accessories for external tibial nerve stimulator (e.g., socks, gel pads, electrodes, etc.), needed for one	10/1/2024
A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit,	10/1/2024
C8000	Support device, extravascular, for arteriovenous fistula	10/1/2024

C9171	Injection, pegulicianine, 1	10/1/2024
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device	10/1/2024
E0683	Non-pneumatic, non-sequential, peristaltic wave compression pump	10/1/2024
E0715	Intravaginal device intended to strengthen pelvic floor muscles during kegel	10/1/2024
E0716	Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel	10/1/2024
E0721	Transcutaneous electrical nerve stimulatory, stimulates nerves in the auricular	10/1/2024
E0737	Transcutaneous tibial nerve stimulator, controlled by phone	10/1/2024
E0743	External lower extremity nerve stimulator for restless legs syndrome, each	10/1/2024
E0767	Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all	10/1/2024
E2513	Accessory for speech generating device, electromyographic	10/1/2024
E3200	Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription	10/1/2024
J0138	Injection, acetaminophen 10 mg and ibuprofen 3	10/1/2024
J1749	Injection, iloprost, 0.1	10/1/2024
J2253	Injection, midazolam (seizalam), 1	10/1/2024
L1653	Hip orthosis, bilateral thigh cuffs with adjustable abductor spreader bar, adult size, prefabricated, off the shelf	10/1/2024
L1821	Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated, off the shelf	10/1/2024
L8720	External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per	10/1/2024

L8721	Receptor sole for use with L8720, replacement	10/1/2024
P9027	Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each	10/1/2024
Q0519	Pharmacy supplying fee for HIV pre-exposure prophylaxis FDA approved prescription injectable drug, per	10/1/2024
Q0520	Pharmacy supplying fee for HIV pre-exposure prophylaxis FDA approved prescription injectable drug, per	10/1/2024
Q4334	Amnioplast 1, per square	10/1/2024
Q4335	Amnioplast 2, per square	10/1/2024
Q4336	Artacent c, per square	10/1/2024
Q4337	Artacent trident, per square	10/1/2024
Q4338	Artacent velos, per square	10/1/2024
Q4339	Artacent vericlen, per square	10/1/2024
Q4340	Simpligraft, per square	10/1/2024
Q4341	Simplimax, per square	10/1/2024
Q4342	Theramend, per square	10/1/2024
Q4343	Dermacyte ac matrix amniotic membrane allograft, per square	10/1/2024
Q4344	Tri-membrane wrap, per square	10/1/2024
Q4345	Matrix hd allograft dermis, per square	10/1/2024

Table 8 – Deleted Codes

[Back to top](#)

Code	Description (Table 8)	Effective Date
0078U	Gene analysis of 16 genes to evaluate risk of opioid-use disorder	9/30/2024

0167U	Test for detection of human chorionic gonadotropin (pregnancy hormone) in blood specimen	9/30/2024
0396U	Microarray testing of embryonic tissue for 300000 DNA single-nucleotide polymorphisms (SNPs), reported as a probability for single-gene germline conditions in pre-implantation genetic testing	9/30/2024
C9150	Xenon xe-129 hyperpolarized gas, diagnostic, per study dose	9/30/2024
J1170	Injection, hydromorphone, up to 4 mg	9/30/2024
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	9/30/2024
J8520	Capecitabine, oral, 150 mg	9/30/2024
J8521	Capecitabine, oral, 500 mg	9/30/2024
J9258	Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg	9/30/2024